CHICAGO & NEW YORK--(BUSINESS WIRE)--Recent decisions by an FDA advisory committee in favor of approving two new cholesterol-lowering drugs will set up another chapter in the ongoing value debate between drugmakers and health insurers, according to Fitch Ratings. The FDA generally follows the recommendations of advisory committees. The two drugs, including one developed by Amgen (brand name Repatha) and one developed by a partnership between Sanofi and Regeneron (brand name Praluent), with more
| < Prev | Next > |
|---|
